The tumor microenvironment (TME) is a complex mass of malignant and nonmalignant cells, signaling molecules, extracellular matrix, and blood vessels. Immunomodulation of the T-cell response within the TME, via inhibition of immune checkpoints and co-inhibitory molecules such as CTLA-4 and PD-1, is a promising cancer therapy. Multiplex immunohistochemistry (mIHC) enables the tracking of multiple markers within the TME, predicting therapeutic response and highlighting new therapeutic targets.Download this poster from Bethyl Laboratories to discover:
- How to unveil cellular phenotypes in the TME
- The differences between one-color IHC, multiplex IHC, and tyramide signal amplification mIHC
- The advantages of mIHC for investigating the TME
